Blackstone, TPG close $17.3B Hologic deal

Hologic, Inc., a global leader in women’s health, has completed its acquisition by funds managed by Blackstone and TPG, moving the company from public to private ownership. The cash transaction is valued at approximately $17.3 billion and is structured at up to $79 per share.

The deal establishes Hologic as a private company and results in its common stock ceasing to trade on, and being delisted from, the Nasdaq Stock Market. The transaction had been previously announced on October 21, 2025 and was approved by Hologic stockholders on February 5, 2026.

Blackstone and TPG describe Hologic as a global leader in advancing women’s health, with a history of innovation in medical technologies focused on detection, diagnosis and treatment. The acquisition is positioned as the start of a new phase of growth and investment for the company under private ownership.

Under the terms of the completed deal, Hologic stockholders will receive $76 per share in cash plus a non‑tradable contingent value right, or CVR, worth up to an additional $3 per share. This brings the total potential consideration to as much as $79 per share in cash.

The CVR entitles holders to potential payments in two installments of up to $1.50 per share each. Any payment will depend on the achievement of specified global revenue goals for Hologic’s Breast Health business in fiscal years 2026 and 2027.

Stock Titan reported the overall cash transaction value at approximately $17.3 billion, reflecting the per‑share terms multiplied across Hologic’s equity base. The CVRs are non‑tradable and their value will be determined solely by future performance against the agreed revenue milestones.

The acquisition is led by funds managed by Blackstone and TPG, both global alternative asset management firms with large private equity platforms. They become the controlling owners of Hologic following the closing of the transaction.

The transaction also includes significant minority investments from a wholly owned subsidiary of the Abu Dhabi Investment Authority and an affiliate of GIC. These institutions join Blackstone and TPG as investors in the privatized Hologic.

Blackstone executives highlighted Hologic’s established position in women’s health and expressed plans to work with the new leadership and TPG to drive the company’s next phase of growth and innovation. TPG leaders emphasized their longstanding focus on healthcare innovation.

In connection with the closing, Hologic announced the appointment of José (Joe) E. Almeida as Chief Executive Officer. Almeida is described as an accomplished medical technology leader and previously served as Chairman, President and CEO of Baxter International Inc.

Almeida succeeds Stephen MacMillan, who recently retired as Chairman, President and CEO after more than 12 years leading Hologic. With the leadership change, Almeida takes responsibility for guiding the company under its new private ownership structure.

In statements issued with the closing, Almeida characterized Hologic as a company with a storied history of innovation in women’s health and said the new ownership provides greater resources to invest in innovation and initiatives supporting its mission of enabling healthier lives around the world.